Anorexia nervosa (AN) is a serious and heritable psychiatric disorder. To date, studies of copy number variants (CNVs) have been limited and inconclusive because of small sample sizes. We conducted a case-only genome-wide CNV survey in 1983 female AN cases included in the Genetic Consortium for Anorexia Nervosa. Following stringent quality control procedures, we investigated whether pathogenic CNVs in regions previously implicated in psychiatric and neurodevelopmental disorders were present in AN cases. We observed two instances of the wellestablished pathogenic CNVs in AN cases. In addition, one case had a deletion in the 13q12 region, overlapping with a deletion reported previously in two AN cases. As a secondary aim, we also examined our sample for CNVs over 1 Mbp in size. Out of the 40 instances of such large CNVs that were not implicated previously for AN or neuropsychiatric phenotypes, two of them contained genes with previous neuropsychiatric associations, and only five of them had no associated reports in public CNV databases. Although ours is the largest study of its kind in AN, larger datasets are needed to comprehensively assess the role of CNVs in the etiology of AN.
Introduction
Anorexia nervosa (AN) is a psychiatric disorder that carries significant morbidity and mortality (Papadopoulos et al., 2009; Arcelus et al., 2011) . Multiple lines of evidence suggest a notable genetic component in the etiology of AN. Twin studies have estimated the heritability (h 2 ) of AN to be 0.5-0.6 (Bulik et al., 2006; Yilmaz et al., 2015) , and genomic efforts are underway to elucidate the role of genome-wide common variation in the etiology of AN Boraska et al., 2014; Duncan et al., 2016) . Considering the important role that copy number variants (CNVs) play in psychiatric phenotypes (International Schizophrenia Consortium, 2008; Cooper et al., 2011; Levinson et al., 2011; Sanders et al., 2011; Bergen et al., 2012; Malhotra and Sebat, 2012; Szatkiewicz et al., 2014) , studies are needed to help elucidate their role Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.psychgenetics.com).
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in AN. To date, only one CNV study in AN has been published, and although none of the well-established pathogenic CNVs associated with psychiatric and neurodevelopmental disorders were observed in individuals with AN, the authors reported a novel 1.5 Mbp deletion in 13q12 in two cases . However, the study was underpowered to detect rare pathogenic CNVs and the preliminary findings pertaining to AN require replication .
The aim of the present study was to assess the prevalence of large, rare CNVs associated previously with schizophrenia, autism, intellectual disability, or developmental delay in individuals with AN.
Materials and methods
We conducted a case-only genome-wide survey for CNVs in 2907 female AN cases included in the Genetic Consortium for Anorexia Nervosa (GCAN), genotyped as a part of the Wellcome Trust Case Control Consortium 3 (WTCCC3) (Boraska et al., 2014) . Patient ascertainment, quality control (QC), and genotyping procedures have been described in detail elsewhere (Boraska et al., 2014) . The WTCCC3 controls included in the primary genomewide association analysis were unavailable for subsequent analyses; therefore, we identified three dbGaP datasets genotyped using the same array as a source of potential controls for our female AN cases of European ancestry. However, despite multiple rounds of rigorous QC, biases pertaining to CNV calling were present. After ruling out ancestry, plate effect, and original affection status reported in dbGaP datasets, we identified differential processing of the intensity files (correction of which was not possible in our case) as the most likely source of this potential bias. Therefore, we decided that a case-only analysis was necessary to ensure the correctness and validity of our results. Genotype data for the majority of the AN cases included in this study are available on the European Genome-phenome Archive (study accession: EGAS00001000913; dataset accession: EGAD000100010 34; https://www.ebi.ac.uk/ega/studies/EGAS00001000913).
As GCAN included DNA samples derived from various tissues (i.e. blood, buccal epithelium, saliva, or cell lines), we removed all nonblood samples to ensure high-quality and high-confidence CNV calls that are not confounded by DNA source, which led to a sample size of 1983 AN cases. Our analysis pipeline, which followed the steps outlined by Szatkiewicz et al. (2014) , is summarized in Fig. 1 CNV calling was performed using PennCNV (June 2011 version) (Wang et al., 2007 (Wang et al., , 2008 Diskin et al., 2008) with parameters appropriate for the Illumina 660W-Quad chip (Illumina Inc., San Diego, California, USA). All other analyses were carried out using PLINK (Purcell et al., 2007) and R (R Development Core Team, 2011) . We implemented strict cutoffs for single-nucleotide polymorphism (SNP) level, sample-level, and CNV-level QC procedures (Supplementary Methods, Supplemental digital content 1, http://links.lww.com/PG/A188). We examined AN cases for large CNVs previously reported to be associated with schizophrenia, autism, intellectual disability, or developmental delay (Cooper et al., 2011; Levinson et al., 2011; Sanders et al., 2011; Malhotra and Sebat, 2012; Sullivan et al., 2012) (Table 1) . We considered all CNV events more than 100 kbp that had more than 50% reciprocal overlap within 20 kbp of a known psychiatric or neurodevelopmental CNV (i.e. at least 50 kbp overlap with a known CNV was required). We also assessed the presence of the 1.5 Mbp 13q12 deletion reported previously in two AN cases (Table 1) . As a secondary aim, we searched for any CNVs that are more than 1 Mbp in size and checked the Database of Genomic Variants public CNV database (DGV; http://dgv. tcag.ca) to determine whether these CNVs were reported in previous studies. A CNV is considered novel if it has less than 50% reciprocal overlap with previously reported CNVs in DGV. We also examined Online Mendelian Inheritance in Men (OMIM; https://www.omim.org) for overlap with known disease genes.
Results
Following rigorous QC, our analysis dataset comprised 2724 high-confidence, rare (< 1% minor allele frequency), large (>100 kbp) CNVs in 1983 cases. Factors affecting the number of CNVs detected include array type used and analytic tools used (detection algorithms and QC procedures), with array type as the primary factor (Pinto et al., 2011; Szatkiewicz et al., 2013; Szatkiewicz et al., 2014) . We observed a mean of 1.37 rare, large CNVs per patient, a rate comparable with what has been reported previously in the literature using similar SNP arrays (Szatkiewicz et al., 2014) .
We observed two instances of CNVs with at least 50% reciprocal overlap with the regions associated with psychiatric and neurodevelopmental disorders (Table 1) . More specifically, there were single instances of deletions in 15q13.3 (associated with autism, schizophrenia, and intellectual disability/developmental delay) and 16p11.12 (distal; deletions not associated with a psychiatric or neurodevelopmental phenotype), respectively. In addition, one AN case had a large deletion in the 13q12 region previously implicated in AN in a preliminary study (hg19 coordinates in Table 1 ; intensity plot in Supplementary Fig. 1 , Supplemental digital content 1, http://links.lww.com/PG/A188); however, whether this CNV is AN specific is uncertain because of the case-only design of our study.
Following candidate CNV analysis, we next examined our dataset for the presence of rare (minor allele frequency < 1%) CNVs over 1 Mbp in size. We identified 42 regions with such large deletions and duplications (Table 2) , including one instance of 15q13.3 and 13q12 deletions each (Table 1) . Out of the remaining 40 CNVs, 18 of them housed a total of 35 genes associated with various Mendelian conditions in OMIM, most of which are not associated with psychiatric or neurodevelopmental phenotypes (Table 2) . However, the 3p26.3 deletion observed in one case spans over the CRBN gene, which is associated with autosomal recessive intellectual disability. Similarly, two genes (SHROOM4 and SYP) located within the Xp11.23 region (in which one case had a large deletion) have been associated previously with X-linked recessive developmental delay and intellectual disability. A duplication in the 22q11.21 region (which does not have 50% overlap with the 22q11 candidate CNV region) includes TBX1, previously linked to velocardiofacial syndrome. Also of interest, three CNV events in our AN database that were not reported in DGV were observed in schizophrenia cases in the PGC CNV database (CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium & Psychosis Endophenotypes International Consortium, 2016).
We could not find previous reports of or frequency information for five of the 42 rare and large CNV events. Although two of them (2p25.1 and 2p25.2) do not contain Experimental workflow and CNV datasets. AN, anorexia nervosa; CNV, copy number variant; GWAS, genome-wide association study; HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; QC, quality control; SNP, single-nucleotide polymorphism. any OMIM disease genes, the remaining three CNV regions (5q11.2, 8p21.1, and 8p21.3) span over OMIM disease genes associated with amyloidosis, hyperlipidemia, hemolytic anemia, and esophageal carcinoma (Table 2) . It is also noteworthy that 10 cases had CNV events (eight duplications and two deletions) in the Xp22.31 region (chrX: 6 458 166-8 141 017; Table 2 ).
The follow-up quantitative PCR experiment examining one deletion and one duplication from this region validated these CNVs successfully (details in Supplementary  Information 
Discussion
In this case-only analysis, two individuals with AN had large, rare CNVs with over 50% reciprocal overlap with regions associated with psychiatric and neurodevelopmental disorders. The frequency with which these CNVs were observed in our sample is consistent with the literature (Levinson et al., 2011; Szatkiewicz et al., 2014) . Furthermore, one AN case in our study had a large deletion in the 13q12 region described previously in two cases with AN . It is noteworthy that there is no frequency information available for the 13q12 deletion in 1000 Genomes, which suggests that the precise population frequency of this CNV is not well known. However, we found three studies in DGV, which reported CNVs in controls with more than 50% reciprocal overlap with the CNV in our study (Pinto et al., 2007; Cooper et al., 2011; Uddin et al., 2015) . Although we cannot rule out a possible AN diagnosis in these individuals, 13q12 deletion does not appear to be AN specific, and its presence in one AN case should be interpreted with caution as larger case-control samples are required to rigorously evaluate the validity of this deletion in AN.
Outside of the well-established neuropsychiatric CNVs, 40 instances of rare and large CNVs were observed in AN cases. Although many of them contained OMIM disease genes, only two of these events (3p26.3 and Xp11.23) had previous associations with psychiatric/neurodevelopmental phenotypes. However, the lack of detailed phenotypic information prevented us from further examining the characteristics of the AN patients with these CNVs. Also of interest, three large CNVs not available in public databases were observed in schizophrenia cases, but not controls in the PGC CNV database, thus suggesting a potential association with schizophrenia that requires replication. Although there were 10 instances of CNV events in the Xp22.31 region in AN cases in our study (whose validity was confirmed by quantitative PCR), this CNV does not appear to be rare and has been reported in healthy controls alongside schizophrenia cases in PGC, and therefore unlikely to be an AN-specific risk CNV. Although this region includes STS, a gene associated with X-linked ichithyosis (a family of skin disorders), there are no known associated medical phenotypes observed in females. It is noteworthy that we failed to detect any clinical patterns involving AN age at onset, lowest illnessrelated BMI, highest-lifetime BMI, or AN subtype among the patients with CNVs in this Xp22.31 region.
Although the present study is the largest AN CNV analysis carried out to date, limitations must be considered. As a case-only design, our analyses focused on the characterization of the large, rare, and well-replicated psychiatric and neurodevelopmental CNVs in individuals with AN, as well as the description of 1 Mbp + CNVs observed in our sample. The GCAN/WTCCC3 AN genomic dataset is challenging because of the ancestral heterogeneity of the component samples, which required us to apply strict QC cutoffs. Furthermore, the WTCCC3 controls used in the primary genome-wide association studies were unavailable for our analysis. We accessed and tested several dbGaP datasets as controls with the goal of investigating CNV burden and searching for novel CNVs associated with AN; however, several technical issues arose caused by the arrays having been processed separately, ultimately leading to the decision to extract as much information as possible from cases by determining whether CNVs in regions implicated in psychiatric and neurodevelopmental disorders were present in AN cases. Furthermore, the lack of detailed clinical phenotype information prevented us from performing a more in-depth examination of whether there are clinical manifestations associated with these CNVs in patients with AN. Although it is possible that some of the CNVs included in our analysis do not confer risk for AN, our study may have been underpowered to detect a few of these rare CNVs, thus potentially failing to capture their actual prevalence in individuals with AN. Future directions include examining a well-matched large case-control sample (ideally around 5000 cases, which would confidently allow for the assessment of known CNVs with 0.1% frequency implicated in other psychiatric disorders in AN) to assess case-control differences in CNV (e.g. genic and genome-wide) as well as searching for novel CNVs that confer risk to AN.
